Novogene announced the addition of Illumina's latest high-throughput sequencing system NovaSeq™ X Plus and PacBio's Revio™ long-read sequencing system to its lineup of sequencing platforms. These systems will be deployed in Novogene's regional lab facilities and will be available to its global customer base. Novogene is a trusted genomics partner to scientists worldwide and provides access to the latest genomics tools to the scientific community. The acquisition of these new platforms is expected to enhance Novogene's capabilities and quality of genomics research services, allowing its customers to handle higher throughput and more ground-breaking research.

NovaSeq™ X Plus is Illumina's high-throughput sequencing system that delivers the best performance in terms of throughput, production capacity and sustainability. It has a throughput of up to 2.5 times that of prior sequencers, and can generate more than 20,000 whole genomes per year, making it ideal for large-scale sequencing projects and ambitious genomics studies. It has the potential to drive down the cost of sequencing and accelerate the adoption of DNA sequencing technologies in a variety of research and clinical applications.

Pacbio's Revio long-read sequencing platform provides customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage. The platform runs up to four SMRT Cells in parallel, which provides up to 100 million zero-mode waveguides (ZMWs) for sequencing single molecules simultaneously. Combined with the significant advance in PacBio's computing capability, Revio is on track to deliver a shorter runtime and a 15-fold increase in HiFi data.